<?xml version='1.0' encoding='utf-8'?>
<document id="26642944"><sentence text="Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases."><entity charOffset="36-44" id="DDI-PubMed.26642944.s1.e0" text="Tyrosine" /></sentence><sentence text="Tyrosine kinase inhibitors (TKIs) are anticancer drugs that may be co-administered with other drugs"><entity charOffset="0-8" id="DDI-PubMed.26642944.s2.e0" text="Tyrosine" /></sentence><sentence text=" The aims of this study are to investigate the inhibitory effects of TKIs on UDP-glucuronosyltransferase (UGT) activities, and to quantitatively evaluate their potential to cause drug-drug interactions (DDIs)" /><sentence text=" Inhibition kinetic profiles of a panel of UGT enzymes (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17) by four TKIs (axitinib, imatinib, lapatinib and vandetanib) were characterized by using hepatic microsomes and recombinant proteins"><entity charOffset="140-148" id="DDI-PubMed.26642944.s4.e0" text="axitinib" /><entity charOffset="150-158" id="DDI-PubMed.26642944.s4.e1" text="imatinib" /><entity charOffset="160-169" id="DDI-PubMed.26642944.s4.e2" text="lapatinib" /><entity charOffset="174-184" id="DDI-PubMed.26642944.s4.e3" text="vandetanib" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e0" e2="DDI-PubMed.26642944.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e0" e2="DDI-PubMed.26642944.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e0" e2="DDI-PubMed.26642944.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e0" e2="DDI-PubMed.26642944.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e1" e2="DDI-PubMed.26642944.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e1" e2="DDI-PubMed.26642944.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e1" e2="DDI-PubMed.26642944.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e2" e2="DDI-PubMed.26642944.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26642944.s4.e2" e2="DDI-PubMed.26642944.s4.e3" /></sentence><sentence text=" Lapatinib exhibited potent competitive inhibition against UGT1A1 activity with a Ki of 0"><entity charOffset="1-10" id="DDI-PubMed.26642944.s5.e0" text="Lapatinib" /></sentence><sentence text="5 μM" /><sentence text=" Imatinib was found to exhibit broad inhibition on several UGTs, particularly potent competitive inhibition against UGT2B17 with a Ki of 0"><entity charOffset="1-9" id="DDI-PubMed.26642944.s7.e0" text="Imatinib" /></sentence><sentence text="4 μM" /><sentence text=" The TKIs also exerted intermediate inhibition against several UGTs (i" /><sentence text="e" /><sentence text=", UGT1A7 by lapatinib; UGT1A1 by imatinib; UGT1A4, 1A7 and 1A9 by axitinib; and UGT1A9 by vandetanib)"><entity charOffset="12-21" id="DDI-PubMed.26642944.s11.e0" text="lapatinib" /><entity charOffset="33-41" id="DDI-PubMed.26642944.s11.e1" text="imatinib" /><entity charOffset="43-49" id="DDI-PubMed.26642944.s11.e2" text="UGT1A4" /><entity charOffset="66-74" id="DDI-PubMed.26642944.s11.e3" text="axitinib" /><entity charOffset="90-100" id="DDI-PubMed.26642944.s11.e4" text="vandetanib" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e0" e2="DDI-PubMed.26642944.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e0" e2="DDI-PubMed.26642944.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e0" e2="DDI-PubMed.26642944.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e0" e2="DDI-PubMed.26642944.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e0" e2="DDI-PubMed.26642944.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e1" e2="DDI-PubMed.26642944.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e1" e2="DDI-PubMed.26642944.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e1" e2="DDI-PubMed.26642944.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e1" e2="DDI-PubMed.26642944.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e2" e2="DDI-PubMed.26642944.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e2" e2="DDI-PubMed.26642944.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e2" e2="DDI-PubMed.26642944.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e3" e2="DDI-PubMed.26642944.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26642944.s11.e3" e2="DDI-PubMed.26642944.s11.e4" /></sentence><sentence text=" Results from modeling for the quantitative prediction of DDI risk indicated that the coadministration of lapatinib or imatinib at clinical doses could result in a significant increase in AUC of drugs primarily cleared by UGT1A1 or 2B17"><entity charOffset="106-115" id="DDI-PubMed.26642944.s12.e0" text="lapatinib" /><entity charOffset="119-127" id="DDI-PubMed.26642944.s12.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.26642944.s12.e0" e2="DDI-PubMed.26642944.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26642944.s12.e0" e2="DDI-PubMed.26642944.s12.e1" /></sentence><sentence text=" Lapatinib and imatinib may cause clinically significant DDIs when co-administered UGT1A1 or 2B17 substrates"><entity charOffset="1-10" id="DDI-PubMed.26642944.s13.e0" text="Lapatinib" /><entity charOffset="15-23" id="DDI-PubMed.26642944.s13.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.26642944.s13.e0" e2="DDI-PubMed.26642944.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26642944.s13.e0" e2="DDI-PubMed.26642944.s13.e1" /></sentence><sentence text="" /></document>